Evidence map›Paper›PMID 39370252›Full record

ArticleInternal medicine (Tokyo, Japan)2025

GLUT-1-negative Choroidal Malignant Melanoma with Liver Metastasis Recurrence 12 Years after Surgery without FDG Accumulation in a Recurrent Lesion on FDG-PET/CT.

Toyoki Shimamoto, Hironori Ochi, Cao Fang, Michiko Amano, Takaaki Tanaka, Nobuaki Azemoto, Toshie Mashiba, Koichi Kimura, Ryosuke Minagawa, Yumi Ooshiro and 2 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Toyoki ShimamotoDepartment of Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Japan.
Hironori OchiDepartment of Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Japan.
Cao FangDepartment of Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Japan.
Michiko AmanoDepartment of Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Japan.
Takaaki TanakaDepartment of Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Japan.
Nobuaki AzemotoDepartment of Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Japan.
Toshie MashibaDepartment of Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Japan.
Koichi KimuraDepartment of Surgery, Matsuyama Red Cross Hospital, Japan.
Ryosuke MinagawaDepartment of Surgery, Matsuyama Red Cross Hospital, Japan.
Yumi OoshiroDepartment of Pathology, Matsuyama Red Cross Hospital, Japan.
Toshio KodamaDepartment of Ophthalmology, Matsuyama Red Cross Hospital, Japan.
Tomoyuki YokotaDepartment of Liver-Biliary-Pancreatic Disease, Matsuyama Red Cross Hospital, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Choroidal malignant melanoma is a rare malignant tumor that develops in adult eyeballs. It causes early lymph node and distant metastasis. Fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (CT) is widely used for screening malignant melanoma metastases. We encountered a 58-year-old man with choroidal malignant melanoma in whom liver metastasis recurred 12 years after surgery, without any observable FDG accumulation. Immunostaining revealed the absence of glucose transporter type 1 (GLUT-1) expression, crucial for intracellular FDG uptake. The lack of FDG accumulation in the lesion could be attributed to the diminished cellular FDG uptake due to the absence of GLUT-1 expression.

Indexed as

Choroid NeoplasmsFluorodeoxyglucose F18Glucose Transporter Type 1Liver NeoplasmsMelanomaNeoplasm Recurrence, LocalPositron Emission Tomography Computed TomographyHumansMaleMiddle AgedRadiopharmaceuticalsFluorodeoxyglucose F18Glucose Transporter Type 1Radiopharmaceuticalschoroidal malignant melanomametastatic liver tumorPET/CT

Identifiers

PMID39370252
PMCPMC12120224

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.